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Abstract 
The aim of this work was to study the potential of pegylated poly(anhydride) 
nanoparticles as carriers for the oral delivery of paclitaxel (PTX). Paclitaxel is an 
anticancer drug, ascribed to the class IV of the Biopharmaceutical Classification 
system, characterised for its low aqueous solubility and to act as a substrate of 
the P-glycoprotein and cytochrome P450.  
For the pegylation of nanoparticles, three different poly(ethylene glycol) (PEG) 
were used: PEG 2000 (PTX-NP2), PEG 6000 (PTX-NP6) and PEG 10000 
(PTX-NP10). The transport and permeability of paclitaxel through the jejunum 
mucosa of rats was determined in Ussing chambers whereas its oral 
bioavailability was studied in rats.  
The loading of PTX in pegylated nanoparticles increased between 3 and 7-
times the intestinal permeability of paclitaxel through the jejunum compared with 
the commercial formulation Taxol®. Interestingly, the permeability of PTX was 
significantly higher for PTX-NP2 and PTX-NP6 than for PTX-NP10.  
In the in vivo studies similar results were obtained. When PTX-NP2 and PTX-
NP6 were administered to rats by the oral route, sustained and therapeutic 
plasma levels of paclitaxel for at least 48-h were observed. The relative oral 
bioavailability of paclitaxel delivered in nanoparticles was calculated to be 70% 
for PTX-NP2, 40% for PTX-NP6 and 16% in case of PTX-NP10.  
All of these observations would be related with both the bioadhesive properties 
of these carriers and the inhibitory effect of PEG on the activity of both P-gp and 
P450 cytochrome. 
Key words: nanoparticles, paclitaxel, poly(ethylene glycol), bioadhesion, oral, 
drug delivery, controlled release. 
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Introduction 
Paclitaxel (C47H51NO14) is a pseudoalkaloid with a diterpenoid structure and a 
molecular weight of 853 Da [1]. Originally, it was extracted from the bark of the 
Pacific yew tree (Taxus brevifolia). Nowadays, it is obtained from the natural 
precursor product 10-deacetyl baccatin III (10-DAB), available in sufficient 
quantities from the European yew tree (Taxus Baccata), which is transformed 
into taxol by a semi-synthetic production process consisted in seven chemical 
steps [2]. 
Paclitaxel acts as an antineoplastic agent due to its inhibitory effect of cellular 
growth by stabilizing the microtubule assembly and, thus, blocking the cell 
replication in the late G2 mitotic phase of the cell cycle [3]. This anticancer drug 
is widely used in the treatment of several carcinomas including breast [4], 
advanced ovarian [5], non small cell lung [6] and colon [7]. In addition, paclitaxel 
is also employed for the treatment AIDS related Kaposi’s sarcoma [8]. 
Paclitaxel is administered to patients via intravenous infusion. Since paclitaxel is 
practically water insoluble with a very low aqueous solubility of less than 0.3 
mg/ml [9], the commercial formulations (i.e. Taxol®, Paxene®) include a mixture 
of Cremophor EL (polyoxyethylated castor oil) and ethanol (1:1, w/w) as solvent 
[10]. However, the use of Cremophor EL is associated with hypersensitivity 
reactions [11] and causes leakage of plasticizers from polyvinyl chloride (PVC) 
infusion bags and polyethylene tubing [12]. In addition, it has been 
demonstrated that this pharmaceutical excipient alters the pharmacokinetic 
behaviour of many drugs administered intravenously, including paclitaxel, by 
increasing the systemic exposure to the drug and reducing the systemic 
clearance [13].  
In the last years, a number of efforts have been performed in order to develop 
paclitaxel oral formulations. This new approach would offer advantages over 
intravenous infusion such as more attractive for patients and would enable the 
development of chronic treatment schedules resulting in sustained plasma 
concentrations above a pharmacologically relevant threshold level [14]. 
Unfortunately, paclitaxel shows a limited bioavailability (<10%) when 
administered orally [15]. This effect is mainly due to its low aqueous solubility 
and dissolution as well as its affinity for intestinal cytochrome P-450 metabolic 
enzymes (i.e. CYP3A4) and the multidrug efflux transporter P-glycoprotein (P-
gp) [16].  
In order to overcome these problems and to enhance the oral bioavailability of 
this anticancer drug, a number of strategies have been proposed. Among 
others, the most popular has been the synthesis of oral absorbable paclitaxel 
analogs and its association or co-administration with a P-gp inhibitor. Thus, 
paclitaxel derivatives such as BMS-275183 [17] and ortataxel [18] have been 
proposed for oral delivery of this anticancer drug. For BMS-275183, its oral 
bioavailability in humans was found to be 24% [17]; although its clinical use is 
limited by its toxicity, mainly related with the induction of peripheral 
neuropathies [17]. For ortataxel, which is not recognised by P-glycoprotein, its 
oral bioavailability was found to be close to 50% [19]. However, its antitumoral 
efficacy is reduced and/or its use may be hampered by its haematological 
toxicity [20]. 
In parallel, another strategy for the improvement of the oral bioavailability of 
paclitaxel has been the design of pharmaceutical formulations able to solubilise 
the drug and, at the same time, to promote its mucosal permeability. In this 
 
aspect, drug delivery systems such as micelles [21], niosomes [22], or PLGA 
nanoparticles have been proposed [23]. Another interesting alternative for the 
formulation of paclitaxel was the use of self-emulsifying or self-microemulsifying 
drug delivery systems [24, 25]. These formulations can contain components 
which act as Pgp/ cytochrome P-450 inhibitors such as polysorbate 20, 
polysorbate 80, Solutol® surfactants and vitamin E TPGS [26]. Pharmacokinetic 
studies conducted in rats showed that the oral bioavailability of paclitaxel in a 
supersaturable self-emulsifying drug delivery systems was about 5-times higher 
than the control [24]. In a similar way, more recently, new solid lipid 
nanocapsules (containing Solutol® HS15) have demonstrated a high ability to 
promote the oral absorption of paclitaxel in rats [15].  
In this context, another approach may be the use of pegylated poly(anhydride) 
nanoparticles. These carriers have been demonstrated a high ability to develop 
bioadhesive interactions within the gut [27] and would facilitate the localisation 
of paclitaxel in close contact with the surface of absorptive cells of the intestine. 
In addition, the presence of poly(ethylene glycol) (PEG) can add a 
supplementary advantage. In fact, it has been described that PEG can 
negatively affect the activity of the P-gp [28] and the CYP isoenzyme 3A4 [29]. 
Thus, the aim of this work was to study the potential of pegylated 
poly(anhydride) nanoparticles as carriers for the oral delivery of paclitaxel. For 
this purpose, pegylated nanoparticles containing paclitaxel were optimized and 
the intestinal permeability of paclitaxel was investigated using the Ussing 
chamber method. Finally, the pharmacokinetics of paclitaxel when incorporated 
in these bioadhesive carriers was also evaluated in rats. 
 
2. Materials and methods 
2.1. Chemicals 
Poly(methyl vinyl ether-co-maleic anhydride) or PVM/MA (Gantrez® AN 119; 
MW 200,000) was kindly gifted by ISP (Barcelona, Spain). Verapamil, glycine 
and glutamine were provided by Sigma–Aldrich (Steinheim, Germany). 2-
hydroxypropyl--cyclodextrin (HPCD) by RBI (Massachusetts, USA). 
Poly(ethylene glycol) with Mw of 2000, 6000 and 10000 Da (PEG 2000; PEG 
6000; PEG 10000) and disodium edetate (EDTA) were supplied by Fluka 
(Switzerland). Paclitaxel (USP 26 grade >99.5%) was purchased by 21CEC 
(London, United Kingdom). Docetaxel (Taxotere) was provided by Sanofi-
Aventis (Paris, France). Taxol® was purchased from Bristol-Myers Squibb (New 
York, USA). Acetone and ethanol were obtained from VWR Prolabo (Fantenay 
sous Bois, France). Rhodamine B isothiocyanate (RBITC) were supplied by 
Sigma (St Louis, USA). Bumetanide was provided by Calbiochem (Meudon, 
France). Deionised reagent water (18.2 M resistivity) was prepared by a water 
purification system (Wasserlab, Pamplona, Spain). All other chemicals used 
were of analytical grade and obtained from Merck (Darmstadt, Germany).  
 
2.2. Preparation of pegylated poly(anhydride) nanoparticles  
Paclitaxel (PTX) was encapsulated in either conventional or pegylated 
poly(anhydride) nanoparticles by a modification of the solvent displacement 
procedure previously described for the preparation of these functionalized 
nanoparticles [27]. Three different types of poly(ethylene glycols) were used: 
PEG 2000, PEG 6000 and PEG 10000.  
2.2.1. Paclitaxel-loaded pegylated poly(anhydride) nanoparticles  
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Poly(ethylene glycol) (12.5 mg) was firstly dispersed in 3 ml of acetone and 
added to a solution of 100 mg of the copolymer of methyl vinyl ether and maleic 
anhydride (Gantrez® AN 119) in 2 ml of the same organic solvent. The resulting 
mixture was maintained under magnetic agitation. On the other hand, paclitaxel 
was dissolved in 0.5 ml of acetone and added to the polymers mixture. Then, 
the organic phase containing PTX, PVM/MA and PEG was magnetically stirred 
for 1 h at room temperature. After this time, nanoparticles were formed by the 
addition of 10 ml of ethanol followed by the addition of 10 ml of an aqueous 
solution containing glycine (50 mg) and disodium edetate (20 mg). After 
homogenisation for 10 min, the organic solvents were eliminated by evaporation 
under reduced pressure (Büchi R-144, Switzerland) and the resulting 
suspensions purified by tangential filtration in Vivaspin tubes at 3000xg for 20 
min. The supernatants were removed and the pellets resuspended in water. 
The purification process was repeated twice and finally, the formulations were 
frozen and then freeze-dried (Genesis 12EL, Virtis, USA) using sucrose (5%) as 
cryoprotector.  
For the identification of the different formulations the following abbreviations 
were used: PTX-NP2 (with PEG 2000), PTX-NP6 (with PEG 6000) and PTX-
NP10 (with PEG 10000). 
2.2.2. Paclitaxel-loaded conventional poly(anhydride) nanoparticles (PTX-
NP) 
Briefly, 10 mg of PTX were dispersed in 5 ml of acetone containing 100 mg 
PVM/MA and incubated for 1 hour under magnetic stirring at room temperature. 
Then, nanoparticles were formed by the addition of 10 ml of ethanol followed by 
the addition of 10 ml of an aqueous solution containing glycine (50 mg) and 
disodium edentate (20 mg). The resulting nanoparticles were purified and and 
lyophilised as described above. 
2.2.3. Poly(anhydride) nanoparticles fluorescently labelled with RBITC 
For bioadhesive studies, conventional (NP) and pegylated nanoparticles were 
fluorescently labelled with RBITC [27]. For this purpose, nanoparticles were 
prepared as described above in the absence of paclitaxel and incubated with 
1.25 mg RBITC at room temperature for 5 min. After adsorption of the marker, 
the nanoparticles were purified by centrifugation and, finally, freze-dried. 
For the identification the following abbreviations were used: NP (conventional or 
naked nanoparticles), NP2 (with PEG 2000), NP6 (with PEG 6000) and NP10 
(with PEG 10000). 
 
2.3. Characterization of nanoparticles 
The mean hydrodynamic diameter and the zeta potential of nanoparticles were 
determined by photon correlation spectroscopy (PCS) and electrophoretic laser 
Doppler anemometry, respectively, using a Zetamaster analyzer system 
(Malvern Instruments, UK). For this purpose, samples were diluted with 
deionised water and measured at 25°C with a scattering angle of 90°.  
The amounts of PEG associated with the nanoparticles were determined by 
quantification of the excipient in the supernatants collected from the purification 
step of nanoparticles using HPLC coupled to an Evaporative Light Scattering 
Detector (ELSD) [30]. Similarly, the poly(anhydride) content of nanoparticles 
was determined using the same HPLC-ELSD experimental conditions [30]. The 
yield of the nanoparticle preparation process was determined by gravimetry 
from freeze-dried samples as described previously [31]. 
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The amount of RBITC loaded in the nanoparticles was determined by 
colorimetry at wavelength 540 nm after degradation with NaOH 0.1 N 
(Labsystems iEMS Reader MF, Finland) [27]. The quantity of loaded RBITC 
was estimated as a difference between its initial concentration added and the 
concentration found after total hydrolysis of nanoparticles in 0.1 N NaOH. For 
the calculations standard curve of RBITC prepared in 0.1 N NaOH medium was 
used (concentration range of 4-30 µg/ml; r>0.999). 
 
2.4. PTX analysis 
The amount of PTX loaded into nanoparticles was quantified by HPLC [32]. The 
chromatographic system was an Agilent 1100 series (Waldbornn, Germany), 
coupled with a UV diode array detection system. Data were analyzed using the 
Chemstation G2171 program (B.01.03). The separation of PTX was carried out 
at 30ºC on a reversed-phase 150 x 3 mm C18 Phenomenex Gemini column 
(particle size 5 µm). The mobile phase, pumped at 0.5 ml/min, was 50:50 
phosphate buffer (0.01 M, pH=2) - acetonitrile and effluent was monitored with 
UV detection at 228 nm. Docetaxel (DCX) was used as internal standard. Under 
these conditions the run time was 14 min and paclitaxel and docetaxel eluted at 
6.1 min and 7.8 min, respectively. PTX and DCX stock solutions in ethanol were 
refrigerated and calibration curves were designed over the range 80–7000 
ng/ml (r2 > 0.999). The limit of quantification was calculated to be 40 ng/ml. 
For analysis, nanoparticles were digested with DMSO (1:5 v/v). The samples 
were transferred to auto-sampler vials, capped and placed in the HPLC auto 
sampler. Then, 10 µL aliquot was injected onto HPLC column. Each sample 
was assayed in triplicate and results were expressed as the amount of PTX (in 
µg) per mg nanoparticles. Similarly, the encapsulation efficiency (E.E.) was 
calculated as follows: 
E.E: (%) = (Qassociated/Qinitial) x 100                                        [Eq. 1] 
where Qinitial was the initial amount of PTX that it was supposed to be added per 
mg of polymer that form the NP and Qassociated was the amount of PTX in 
digested nanoparticles, which was calculated from the HPLC measurements. 
 
2.5. Permeation assays in Ussing chambers 
The studies were performed after approval by the responsible Ethical 
Committee of the University of Paris-Sud (agreement number A92-019-01) in 
strict accordance with the European legislation in animal experiments. 
2.5.1. Permeation experiments 
Ussing chambers were used to evaluate the permeability of paclitaxel in fresh 
intestinal tissue when loaded in pegylated-poly(anhydride) nanoparticles. For 
this purpose, the methodology and terminology used in this work were those 
proposed previously [33]. Jejunum from fresh small intestine of sacrificed male 
Wistar rats (250 g; Charles River, Paris) was excised, rinsed with chilled 
physiological saline solution (NaCl 0.9%) and cut into segments of 2-3 cm 
length. Sections containing Peyer’s patches were discarded.  
Jejunum portions were mounted in Ussing chambers (the intestinal surface 
tested was 1 cm2) and bathed with PBS at pH 7.4 containing glutamine 0.2 M. 
The system was maintained at constant temperature and continuously 
oxygenated with O2/CO2 (95%/5%). 
In the receptor compartment, 0.1% (w/v) HPCDwas also included as paclitaxel 
solubilising agent. Finally, after equilibration at the temperature of the 
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experiment (4ºC or 37ºC) for 30 min, the formulation to be tested was added to 
the donor compartment. For this purpose, nanoparticle batches containing 2 mg 
paclitaxel were resuspended in 300 µl of PBS (pH 7.4) prior to the addition to 
the donor chamber. Control tests were carried out with the same dose of PTX (2 
mg) included in Taxol and poly (anhydride) nanoparticles.  
At pre-set time intervals, aliquots of 200 µL were recovered from the receptor 
chamber and replaced with the same volume of fresh medium pre-equilibrated 
at the experimental temperature conditions (4ºC or 37ºC). Samples (200 µl) 
were also taken from the donor chamber at the beginning and at the end of the 
experiment to monitor any changes in donor drug concentrations during the 
experiment and to safeguard mass balance. The samples were immediately 
frozen and stored at -20ºC until analysis. 
PTX content was determined by HPLC-UV as described above. Three tissue 
portions from three different animals were used to evaluate each formulation. 
The experiments were repeated on different days. 
The cumulative amount of paclitaxel permeating in the mucosal-to-serosal (M to 
S, absorptive, or apical to basolateral) or serosal-to-mucosal (S to M, secretory, 
or basolateral to apical) direction was calculated and plotted against time. Also, 
the influence of different parameters (such as the temperature, the inhibition of 
the bioadhesion capacity of nanoparticles or the inhibition of P-gp with 
verapamil) on the permeability of intestinal tissue to paclitaxel was also studied. 
In order to determine the influence of the bioadhesive capacity of nanoparticles 
on the absorption of paclitaxel, permeation studies were repeated avoiding the 
physical contact between the nanoparticles and the intestinal mucosa. In 
practice, a semi-permeable cellulose membrane (cut-off: 100,000 g/mol) was 
placed in the donor chamber at the surface of the luminal side of the intestinal 
mucosa. Further, the influence of the presence of verapamil on the permeability 
of paclitaxel was studied by adding 0.2 mM of this calcium blocker to the PBS 
solution in which the paclitaxel formulations were dispersed. 
For comparisons, the following parameters were calculated: the apparent 
permeability coefficient (Papp), the absorption enhancement ratio (R) and the 
efflux ratio (Er). 
The apparent permeability coefficient (Papp) was calculated using the following 
equation: 
Papp =  (dQ/dt) x (1/C0 A)     [Eq. 2] 
where dQ/dt was the flux of PTX from the donor to receptor compartment of the 
mucosa, C0 was the initial concentration of PTX in the donor compartment and 
A was the area of the membrane formed by the intestinal tissue.  
 
The values of Papp were calculated between 30 and 90 min after addition of the 
PTX formulation in all experiments, in order to standardize the calculations.  
The absorption enhancement ratio (R) was calculated from Papp values as 
follows: 
R = Papp (sample) / Papp (control)                                    [Eq. 3] 
where Papp (sample) was the apparent permeability of jejunum to paclitaxel 
when included in the formulation tested and Papp (control) was the apparent 
permeability to the drug when included in the reference formulation (Taxol®). 
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Finally, the efflux ratio (Er) was calculated as the ratio from the mean Papp 
measured from serosal-to-mucosal transport (S to M) and the mean measured 
from mucosal-to-serosal transport (M to S):  
Er = Papp S-M / Papp M-S                                                           [Eq. 4] 
2.5.2. Measurement of electrical parameters 
Electrical parameters were also recorded to determine the tissue viability and 
the opening of tight junctions during the experiment. Transmucosal potential 
difference (PD) was continuously recorded between two KCl saturated agar 
bridges connected to an MDVC – 2C voltage clamp (Titis Bussines Corporation, 
Paris, France) via calomel electrodes filled with saturated KCl solution. Potential 
difference was short-circuited through the experiment by a short-circuit current 
(Isc) via agar bridges placed in each half-cell, and adapted to platinum 
electrodes connected to an automatic MDVC – 2C voltage clamp (Titis 
Bussines Corporation, Paris, France). Delivered Isc  (short – circuited current) 
was corrected for fluid resistance and recorded at pre – set times. The 
transmucosal electrical resistance (TEER) was calculated from the Ohm’s law: 
TEER = PD / Isc                                          [Eq. 5] 
where PD was the transmucosal potential difference and Isc was the potential 
short circuited current. 
 
Only tissues showing PD > 2.10-3 V and Isc > 40.10-6 A/cm2 after 30 min 
equilibration were retained for the study. As a further test of the viability of the 
tissues, bumetanide DMSO stock solution (0.01 M) was added in the serosal 
compartment at the conclusion of the experiment. If there was no decrease in 
Isc, damages in the tissue were suspected and samples collected from the 
corresponding chambers were discarded. 
 
2.6. In vivo bioadhesive study 
The bioadhesion study was carried out using a protocol described previously 
[31], after approval by the responsible Committee by the University of Navarra 
(Ethical and Biosafety Committee for Research on Animals; protocol 078-07), in 
line with the European legislation on animal experiments (86/609/EU). 
Each animal received a single oral dose of 1 ml aqueous suspension containing 
10 mg of the nanoparticles loaded with RBITC (approximately 45 mg 
particles/kg body weight). The animals were sacrificed by cervical dislocation 
one and three hours post-administration. The abdominal cavity was opened and 
the stomach, small intestine and cecum were removed, opened lengthwise 
along the mesentery and rinsed with phosphate saline buffer (pH 7.4). Further, 
the stomach, small intestine and cecum were digested in 3 N NaOH for 24 h. 
RBITC was extracted from the digested samples by addition of methanol, 
vortexed for 1 min and centrifuged at 4,000 rpm for 10 min. The samples were 
then analysed by spectrofluorimetry at λex 540 nm and λem 580 nm (GENios 
Tecan, Austria) to estimate the fraction of adhered nanoparticles on the 
mucosa. For calculations, standard curves of RBITC were prepared by addition 
of RBITC-solutions in 3 N NaOH (0.5-10 µg/ml) to tissue segments following the 
same treatment steps (r>0.996).   
 
2.7. Pharmacokinetic study of paclitaxel in rats 
Animal experiments were performed according to the policies and guidelines of 
the responsible Committee of the University of Navarra in line with the 
 

European legislation on animal experiments (86/609/EU) and following a 
protocol approved by the Ethic Committee of the University of Navarra (protocol 
number 076-06). 
2.7.1. Administration of PTX-loaded pegylated nanoparticles to rats 
Male Wistar rats (average weight 225 g) (Harlan, Spain) were housed under 
normal conditions with free access to food and water. The animals were placed 
in metabolic cages and fasted overnight to prevent coprophagia but allowing 
free access to water. 
For the pharmacokinetic study, the rats were divided at random in seven groups 
(n=6). The first group received intravenously by the vein of the tail 10 mg/kg of 
paclitaxel as Taxol® (commercial formulation) diluted with PBS until a final 
volume of 500 µl. The other groups of animals received paclitaxel (10 mg/kg) in 
different formulations by oral administration: (i) Taxol; (ii) PTX-NP2; (iii) PTX-
NP6; (iv) PTX-NP10 and (v) PTX-NP. All the animals received orally a total 
volume of 1 ml of either Taxol diluted with saline or nanoparticles dispersed in 
water just before the administration. 
After administration, blood samples of 300 µl were collected at different times 
post-administration. EDTA was employed as anticoagulant. The volemia was 
recovered via intraperitoneal with an equal volume of normal saline solution 
preheated at body temperature. Blood samples were centrifuged for 10 min at 
10,000 rpm and the supernatant plasma fraction was stored at -80ºC until HPLC 
analysis. 
2.7.2. HPLC quantification of paclitaxel in plasma samples 
The amount of paclitaxel was determined in plasma by HPLC as described 
above. Calibration curves were used for the conversion of the PTX/DCX 
chromatographic area to the concentration. Calibrator and quality control 
samples were prepared by adding appropriate volumes of standard PTX 
ethanolic solution to drug free plasma. Calibration curves were designed over 
the range 40–3200 ng/ml (r2>0.999). An aliquot (100 µl) of plasma sample was 
mixed with 25 µl of internal standard solution (docetaxel, 4 µg/ml in methanol, 
previously evaporated). After vortex mixing, liquid-liquid extraction was 
accomplished by adding 4 ml of tert-buthylmethylether following vortex gentle 
agitation (1 min). The mixture was centrifuged for 10 min at 5,000 rpm, and 
then, the organic layer was transferred to a clean vial and evaporated until dry 
(Savant, Barcelona, Spain). Finally, the residue was dissolved in 125 µl of 
reconstitution solution (acetonitrile – phosphate buffer 0.01M pH=2; 50/50 v/v) 
and transferred to auto-sampler vials, capped and placed in the HPLC auto 
sampler. A 100 µl aliquot of each sample was injected onto the HPLC column. 
The limit of quantification was calculated as 80 ng/mL with a relative standard 
deviation of 5.2%. Accuracy values during the same day (intra-day assay) at 
low, medium and high concentrations of PTX were always within the acceptable 
limits (less than 5%) at all concentrations tested. 
2.7.3. Pharmacokinetic data analysis 
The pharmacokinetic analysis of concentration-time data, obtained before the 
administration of the different PTX formulations, was analyzed using a 
noncompartimental model using WinNonlin 5.2 software (Pharsight Corporation, 
Mountain View, EEUU). The pharmacokinetic parameters estimated were: the 
maximal plasmatic concentration (Cmax), time in which the maximum 
concentration was reached (Tmax), the half-life of the terminal phase (t1/2), the 
area under the concentration-time curve from time 0 to ∞ (AUC0-∞) and the 
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mean residence time (MRT). The relative bioavailability of paclitaxel (FR) was 
calculated according to the following equation: 
FR  = (AUCoral / AUCiv) x 100                                                    [Eq. 6] 
where AUCoral was the area under the concentration versus time curve after oral 
administration and AUCi.v. was the AUC for Taxol® administered by the i.v. 
route. 
 
2.8. Statistical analysis 
The permeability values and pharmacokinetic results were expressed as mean 
values ± SD. The nonparametric Kruskal-Wallis followed by Mann-Whitney U-
test with Bonferroni correction was used to investigate statistical differences. In 
all cases, p < 0.05 was considered to be significant. All calculations were 
performed using SPSS® statistical software program (SPSS® 15.0, Microsoft, 
USA).   
 
3. Results 
3.1. Preparation and characterisation of PTX-PEG poly(anhydride) 
nanoparticles  
Nanoparticles were prepared after the incubation of a mixture of poly(anhydride) 
and PEG with the anticancer drug. Then the polymer was desolvated by the 
addition of ethanol and water and the resulting nanoparticles were freeze-dried 
after purification. For the optimization of paclitaxel-loaded pegylated 
nanoparticles, the effect of the bulk concentration of paclitaxel (expressed as 
the ratio between the drug and the polymer) on the drug loading was evaluated. 
Figure 1 shows the evolution of the paclitaxel loading in the different pegylated 
nanoparticles as a function of the PTX/poly(anhydride) ratio. Interestingly, for all 
the different formulations tested, by increasing the amount of the bulk paclitaxel, 
the drug loading increased sharply until a PTX/poly(anhydride) ratio of 0.1. 
However, at ratios higher than 0.1, aggregation of the nanoparticle was 
observed. 
At a PTX/poly(anhydride) ratio of 0.1, the total amount of encapsulated 
paclitaxel was similar for the different pegylated nanoparticles (irrespective of 
the MW of PEG) and close to 150 µg drug per mg nanoparticles. For control 
nanoparticles, the maximum drug loading was calculated to be about 80 µg of 
PTX per mg/nanoparticles.  
The main physico-chemical characteristics of PTX-PEGylated poly(anhydride) 
nanoparticles used in this work are summarised in Table 1. Control 
nanoparticles (PTX-NP) displayed a mean size of 177±3 nm and a zeta 
potential close to -45 mV. Pegylation of poly(anhydride) nanoparticles did not 
modified the mean particle size; although, the zeta potential was found to be 
slightly lower than that of control nanoparticles. Furthermore, the yield of the 
preparative process was similar for all the formulations and close to 60-65%. 
Finally, the PTX encapsulation efficiencies were found to be more than 2-times 
higher for pegylated nanoparticles than for control ones. Overall all the 
pegylated nanoparticles displayed similar physico-chemical characteristics, 
independently of the MW of the PEG used for pegylation. 
 
3.2. Permeability studies in Ussing chambers 
The transport and permeability of paclitaxel through the jejunum mucosa of rats 
was determined “ex vivo” in Ussing chambers. Table 2 summarizes the 
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apparent permeability coefficients, Papp in cm/s, and the absorption 
enhancement ratios (R) of paclitaxel calculated for the different formulations 
tested.  
In the M-S direction, the apparent permeability of paclitaxel when formulated as 
Taxol® was found to be very low (about 1.2 x 10-6 cm/s). For the control 
formulation of paclitaxel loaded in conventional nanoparticles (PTX-NP), the 
apparent permeability was slightly higher than for Taxol® (about 2.1 x 10-6 
cm/s). On the contrary, when PTX was incorporated in pegylated nanoparticles 
(PTX-NP2, PTX-NP6 and PTX-NP10) the intestinal permeability of paclitaxel 
increased between 3 and 7 times compared with the commercial formulation. 
Interestingly, the permeability of PTX was significantly higher when the drug 
was loaded in nanoparticles pegylated with either PEG 2000 or PEG 6000 than 
when decorated with PEG 10000 (p<0.005).  
When the apparent intestinal permeability of PTX (Taxol) was studied in the 
secretory direction (S-M), the paclitaxel permeability was found to be much 
higher than that observed in the absorptive direction (M-S). Thus, for Taxol®, 
the absorption enhancement ratio (R) was about 27 times higher than when 
evaluated in the mucosal-to-serosal direction. Similarly, when drug was 
formulated in pegylated nanoparticles (PTX-NP2), the Papp value was found to 
be about 22 x 10-6 cm/s, which represented an efflux ratio of about 2.5.  
On the other hand, it is well known that paclitaxel is substrate of the P-
glycoprotein. Thus, when P-glycoprotein was inhibited with verapamil, the 
permeability of paclitaxel was 3-times higher than in normal conditions (see 
Table 2). On the contrary, when contact between PTX-NP2 and the intestinal 
tissue was hampered by the presence of a semi-permeable membrane, 
paclitaxel was unable to be absorbed through the intestinal tissue and the 
apparent permeability was very low (Papp= 0.3 x 10-6cm/s). 
 
3.3. In vivo bioadhesión study 
In vivo bioadhesive studies were performed using RBITC-labelled nanoparticles 
(Figure 2). Thus, 1 h post-administration, conventional nanoparticles (NP) 
displayed a higher ability to interact with the stomach mucosa than pegylated 
nanoparticles. On the contrary, in the small intestine, nanoparticles pegylated 
with either PEG 2000 (NP2) or PEG 6000 (NP6) interacted in a significantly 
higher extent with the mucosa than NP or NP10 (p<0.01). In fact, for NP2 and 
NP6, around 23% of the given dose was found adhered to the small intestine 
mucosa, whereas only 12% for NP and 9% for NP10 was quantified in this gut 
region.  
On the other hand, 3-h post-administration, the adhered fraction of 
nanoparticles in the small intestine was similar for the three pegylated 
nanoparticles (between 23-27% of the given dose). These amounts were 
significantly higher than for NP (p<0.01). In the stomach, the amount of 
nanoparticles found where much lower and similar for all the formulations tested 
(less than 5 % of the given dose). 
 
3.4. Pharmacokinetics of paclitaxel in rats 
Figure 3 shows the paclitaxel plasma concentration versus time profile after 
intravenous administration of Taxol at a dose of 10 mg/kg in rat. As expected, 
the drug plasma concentration rapidly decreased with time in a biphasic way 
and the data were adjusted by noncompartmental model. The peak plasma 
 
concentration (Cmax) of paclitaxel was about 204 g/ml. The mean values 
obtained for AUC and half-life (T1/2z) were 81 g ml−1 h−1 and 2.6 h, respectively. 
The MRT was 1.7 h (Table 3).  
Figure 4 shows the plasma concentration versus time profile after oral 
administration of paclitaxel (single dose of 10 mg/kg) included in the different 
nanoparticle formulations. When commercial Taxol was administered to rats by 
the oral route, PTX plasmatic levels detected were very low; always under the 
quantification limit of the HPLC technique (80 ng/ml). On the contrary, when 
paclitaxel was loaded in pegylated poly(anhydride) nanoparticles, sustained 
plasma levels of the anticancer drug were observed. These plasma curves were 
characterised by increasing amounts of paclitaxel in plasma during the first 3-6 
h followed by a step in which the drug plasma concentration was maintained at 
high and constant levels until 10 h (for PTX-NP10) or 48 h post administration 
(for PTX-NP2 and PTX-NP6). During this second step, it was observed that 
PTX-NP2 displayed higher levels of PTX than PTX-NP6. Finally, the paclitaxel 
plasma concentration decreased rapidly; although, 72 h post-administration, 
quantifiable amounts of drug were still found. For conventional nanoparticles, in 
spite of higher than for Taxol®, the plasma levels of paclitaxel remained low and 
close to the defined therapeutic concentration (85 ng/ml; [25]). 
Table 3 summarizes the pharmacokinetic parameters estimated with a non-
compartmental analysis of the experimental data obtained after the oral 
administration of the different PTX formulations to rats. As seen in Table 3, the 
paclitaxel Cmax for the nanoparticle formulations were found to be about 100-
120 times lower than that of the drug formulation administered by the i.v. route. 
On the contrary, Cmax for pegylated nanoparticles was about 9-14 fold higher 
than that of conventional nanoparticles. Within the different pegylated 
nanoparticles, the rank order of the mean maximum plasma drug concentration 
among the different formulations was as follows: PTX–NP2 = PTX–NP6 > PTX-
NP10 (p< 0.05). Similarly, the AUC values were found to be dependent on the 
molecular weight of PEG used in the formulation. For PTX-NP2 and PTX-NP6 
oral formulations, AUC values were 4.3 and 2.5-folds respectively higher than 
the AUC obtained for PTX-NP10 administered at the same dose of the drug. 
In addition, the mean residence time (MRT) of the drug in plasma and the t1/2 
were found higher when paclitaxel was administered in the nanoparticle 
formulations by the oral route than when administered as Taxol® by the i.v. 
route. For PTX-NP2 and PTX-NP6, the MRT of paclitaxel was higher than for 
PTX-NP10. On the contrary, PTX-NP10 showed a terminal elimination half-life 
of paclitaxel of about 4.6 and 3.1-fold higher than for PTX-NP6 and PTX-NP2 
respectively.  
Finally, the relative oral bioavailability of paclitaxel delivered in nanoparticles 
was calculated to be 70% for PTX-NP2, 40% for PTX-NP6 and 16% in case of 
PTX-NP10. For non pegylated nanoparticles the oral bioavailability was found to 
be only 9%. 
 
4. Discussion 
Paclitaxel, classified as class IV drug of the biopharmaceutical classification 
system, shows a very low bioavailability when administered by the oral route. 
This fact is due to both its low aqueous solubility (lop P = 3.5) and low intestinal 
permeability mainly due the effect of the P-glycoprotein and cytochrome P450 
(i.e. CYP3A4) expressed in the epithelial enterocytes [16, 34, 35].  
 
In order to overcome these drawbacks and increase the intestinal permeability 
of paclitaxel one possible strategy may the combination between bioadhesive 
nanoparticles and excipients capable to inhibit the activity of Pgp and/or the 
cytochrome P450. In this context, the use of pegylated poly(anhydride) 
nanoparticles may be of interest for this purpose. These nanoparticles have 
shown a high ability to cross the mucus layer and reach the surface of the 
enterocytes [27]. In addition, PEG has shown a moderate inhibitory effect of 
both P-gp and CYP3A4 [36].  
Pegylated nanoparticles were prepared by a simple incubation of paclitaxel, 
polyethylenglycol and the poly(anhydride) in an acetone medium followed by 
the desolvation of the polymers with ethanol and water. During the desolvation 
step glycine was added to promote the encapsulation of paclitaxel in the 
resulting nanoparticles. The exact mechanism by which this amino acid 
augmented the paclitaxel loading has not been yet elucidated; although, glycine 
has been described as an auxiliary substance to promote the solubility of 
lipophilic compounds (i.e. dehydroepiandrosterone) [37]. In any case, this 
increase in the encapsulation efficiency of paclitaxel was particularly impressive 
for conventional nanoparticles, in which the addition of glycine enabled us to 
increase the drug loading from 0.3 µg/mg nanoparticle (not shown) to close to 
80 µg/mg (Table 1). Interestingly, the amount of paclitaxel loaded in pegylated 
nanoparticles was not dependent on the MW of the PEG employed for 
pegylation and was calculated to be about 150 µg/mg nanoparticles (about 15% 
w/w). This fact is in agreement with previous results published by Bartoli and 
collaborators (1990) [38] who described a significant increase of paclitaxel 
loading in pegylated liposomes, in comparison with plain liposomes.  
Concerning the studies of permeability of paclitaxel in Ussing chambers, the 
differences in the drug permeation rates observed in the mucosal-to-serosal 
direction vs. serosal-to-mucosal orientation is a classical indication that efflux 
pump is involved in the transport of the drug across the jejunum tissue [39]. The 
asymmetric permeation found for free paclitaxel (Taxol) (Papp M-S 1.2 vs. Papp S-
M 32.1; Table 2) and an efflux ratio (calculated by eq. 4) of about 27, confirmed 
the presence of an active mechanism, such as apically polarized efflux proteins, 
for which paclitaxel is a very good substrate [40]. The involvement of P-
glycoprotein in the intestinal absorption of paclitaxel included in pegylated 
nanoparticles (PTX-NP2) was confirmed by the addition of the calcium blocker 
verapamil (a well known inhibitor of the P-gp efflux pump [14]) at a 
concentration of 0.2 mM on the apical side. The apparent permeability 
coefficient of paclitaxel was found to be 3-fold higher when verapamil was 
added to the donor compartment containing the PTX-NP2 formulation. 
On the other hand, when PTX was included in pegylated nanoparticles, the 
permeability of the anticancer drug significantly increased as compared with the 
controls (Taxol® and PTX-NP), confirming a significant decrease in the efflux 
transport of paclitaxel which can be considered as a clear evidence of inhibition 
of the active secretory transport of paclitaxel by these pegylated carriers. 
However, this positive effect of pegylated nanoparticles on the permeability of 
paclitaxel appeared to be influenced by the molecular weight of the PEG used. 
In fact, the apparent permeability of paclitaxel when loaded in nanoparticles 
pegylated with either PEG 2000 or PEG 6000 was 2.5-times higher than when 
loaded in nanoparticles pegylated with PEG10000. Interestingly, nanoparticles 
pegylated with either PEG 2000 or PEG 6000 displayed higher bioadhesive 
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properties than nanoparticles pegylated with PEG 10000 (see Figure 2). In any 
case, the importance of the bioadhesive interactions between nanoparticles and 
the mucosa for the absorption of paclitaxel was highlighted by the introduction 
of a membrane between the jejunum and the suspension of nanoparticles. 
Under these experimental conditions, paclitaxel was not able to pass through 
the jejunum tissue and the apparent permeability was found to be 28-fold lower 
than under normal conditions. This observation confirmed that the close contact 
between nanoparticles and the mucosa tissue is a key point to enhance the 
absorption of paclitaxel and is in agreement with previous results in which 
paclitaxel was loaded in bioadhesive cyclodextrin-poly(anhydride) nanoparticles 
[32]. 
For the pharmacokinetic study, a single-dose of 10 mg/kg was selected. When 
Taxol® was administered by the intravenous route, the profile of the curve was 
biphasic (Figure 3) and similar to that published previously. From the plasma 
curve, the mean AUC and the terminal half life (t1/2z) for paclitaxel was 
calculated to be about 81 µg/h ml and 2.6 h. These values were consistent with 
data previously reported of paclitaxel administered in rats at the same dose [21, 
25, 41, 42]. On the contrary, when Taxol® was administered by the oral route, 
the plasma levels of paclitaxel were negligible (not shown) and it was not 
possible to calculate the relative oral bioavailability (Fr) of paclitaxel when 
formulated in the commercial formulation. In any case, Fr of paclitaxel when 
orally administered has been reported to be between 2 and 10.5% [15, 25, 43].  
When paclitaxel was loaded in pegylated nanoparticles and orally administered 
to rats, the plasma levels of paclitaxel were high and prolonged in time (Figure 
4). However some differences in the profile of the curves were found. Thus, the 
peak of the maximum concentration (Cmax) of paclitaxel in plasma was found to 
be dependent on the MW of PEG associated with the nanoparticles. In fact, the 
Cmax value decreased by increasing the MW of the PEG used for the pegylation 
of nanoparticles. On the other hand, for PTX-NP2 and PTX-NP6, the levels of 
paclitaxel in plasma remained high and constant from 48 h; although, the 
plateau of paclitaxel concentration was higher for PTX-NP2 than for PTX-NP6. 
On the contrary, the profile of the curve for PTX-NP10 was characterised by a 
slow decrease of paclitaxel plasma levels after from the Cmax of the curve till 32 
h post-administration. From these curves, the relative oral bioavailability of 
paclitaxel was calculated to be about 70% for PTX-NP2, 40% for PTX-NP6 and 
16% in the case of PTX-NP10, whereas for non pegylated nanoparticles (PTX-
NP) FR was about 9%. These results are in agreement with data obtained form 
the ex vivo studies in Ussing chambers (see Table 2) in which PTX-NP2 and 
PTX-NP6 offered the highest values of permeability across the jejunum of 
animals. Overall all of these results confirm that this type of nanoparticles may 
be of interest to reduce the impact of the efflux pump P-gp and the 
metabolisation effect by cytochrome P450 and, hence, create favourable 
conditions for enhancing the absorption of paclitaxel.  
Overall, all the relative bioavailability data obtained with the different pegylated 
formulations was high. For PTX-NP2, the oral bioavailability of paclitaxel was 
found to be of the same order that those previously reported with cyclodextrin-
poly(anhydride) nanoparticles. These carriers offer a paclitaxel FR of about 80% 
when poly(anhydride) nanoparticles were loaded with the anticancer drug as 
complex with either hydroxypropyl--cyclodextrin or -cyclodextrin [44]. Similar 
bioavailability levels were also reported by Khandavilli and Panchagnula (2007) 
 
[42] by incorporating paclitaxel in a nanoemulsion formulation of a mixture of 
labrasol and vitamin E-TPGS (3:1).  
However, in our case, particularly interesting resulted the performance of 
pegylated nanoparticles to prolong the therapeutic plasma levels of paclitaxel 
for at least 48 h in rats. It is interesting to note that a such plasma profile, 
characterised by relatively stable drug blood levels, would provide a more 
consistent therapeutic effect than frequent doses of short acting medications. In 
addition, fewer peaks and valleys oscillations may result in fewer side effects. 
For PTX-NP2 and PTX-NP6, the paclitaxel plasma concentration were 
maintained in a high and constant level from 3 to 48 h post-administration with 
values till around 20-fold higher than the reported therapeutic range of 0.1 
µmol/L (equivalent to 85 ng/ml [25, 45]). This phenomenon has also been 
observed for cyclodextrin-poly(anhydride) nanoparticles [44] and 
nanoemulsions [42]. However, in these cases, the persistence of high paclitaxel 
plasma levels was restricted to a period of time of 24 h or 18 h, respectively. 
The long persistence of paclitaxel in plasma when formulated with pegylated 
nanoparticles was also confirmed by the calculated MRT data (Table 3). MRT 
values of paclitaxel when formulated as PTX-NP2 and PTX-NP6 (26 h) were 
found to be 18 times higher than the MRT calculated for paclitaxel i.v. 
administered as Taxol (1.7 h).  
All of these results appear to be related with the bioadhesive properties of the 
different pegylated nanoparticles. Thus, pegylation of nanoparticles with either 
PEG 2000 or PEG 6000 yielded carriers capable to develop more appropriate 
adhesive interactions than nanoparticles pegylated with PEG 10000 (see Figure 
2). This finding may be due to a lower interaction between the components of 
the mucus layer of nanoparticles pegylated with either PEG 2000 or PEG 6000 
than with PEG 10000. In the past we demonstrated that the adhesive 
interactions of conventional poly(anhydride) nanoparticles were mainly 
restricted to the mucus layer [46]. When these nanoparticles were pegylated 
with PEG 2000, the PEG chains adopted a “brush” conformation that would 
facilitate their diffusion across the mucus protective layer [27, 47]. A similar 
behaviour can be expected from nanoparticles pegylated with PEG 6000. On 
the contrary, for nanoparticles pegylated with PEG 10000, the disposition of the 
PEG chains covering the surface of nanoparticles would favour the 
interpenetration and interaction with the mucus fibers [48]. This explanation is in 
agreement with Lai and co-workers who hypothetised that coating particles with 
PEG, may reduce particle–mucus adhesive interactions if the molecular mass of 
PEG was too low (< 10 kDa) to support adhesion by polymer interpenetration 
[49].  
As a result pegylated nanoparticles with either PEG 2000 or 6000 would be 
located at the surface of the absorptive membrane for a long period of time and 
during this period they would release their content. The presence of PEG in 
close contact with the surface of mature enterocytes would facilitate the 
inhibition of the P-gp and the cytochrome P450 and, thus, the absorption of 
paclitaxel as suggested by permeation experiments. In any case, these 
hypothetical processes of interactions between nanoparticles and the mucosa 
require further investigations. 
In summary, this study has demonstrated the capability of pegylated 
poly(anhydride) nanoparticles to increase the oral permeability and to prolong 
for at least 48 h sustained and therapeutic plasma levels of paclitaxel in rats. 
 
These effects would be related with the diffusion abilities of these carriers 
through the mucus layer and, probably, with the reported inhibitory effect of 
PEG on P-gp and P450 cytochrome. Particularly interesting were the results 
obtained with nanoparticles pegylated with PEG 2000 and PEG 6000 which 
provided a relatively oral bioavailability of paclitaxel in rat of about 70% and 
40%, respectively. 
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Table 1. Characterization of PTX-loaded pegylated poly (anhydride) 
nanoparticles. Data expressed as the mean ± SD (n=8). PTX-NP: paclitaxel-
loaded poly(anhydride) nanoparticles; PTX-NP2: paclitaxel loaded in 
nanoparticles pegylated with PEG 2000; PTX-NP6: paclitaxel loaded in 
nanoparticles pegylated with PEG 6000; PTX-NP10: paclitaxel loaded in 
nanoparticles pegylated with PEG 10000. PDI: polydispersion index. 
 
Formulation Size (nm) PDI 
Zeta 
Potencial 
(mV) 
Yield 
(%) 
PTX 
loading 
(µg/mg 
NP) 
Encapsulation 
Efficiency (%) 
PTX-NP 177±3 0.038 -44.2±7.1 62.2±1.1 78.1±3.2 38.2±5.3 
PTX-NP2 178±4 0.154 -40.3±1.1 60.1±1.2 150.1±5.2 88.3±7.4 
PTX-NP6 180±5 0.173 -39.5±4.2 63.8±2.1 144.1±3.1 78.1±7.3 
PTX-NP10 188±2 0.136 -41.1±1.3 63.1±0.8 144.5±6.4 74.9±6.2 
 

Table 2. Apparent intestinal jejunum permeability of paclitaxel under different 
experimental conditions as determined using the Ussing Chambers. Each value 
represents the mean Papp ± S.D (n = 4). M-S: mucosal-to-serosal direction; S-M: 
serosal-to-mucosal direction. PTX-NP: paclitaxel-loaded poly(anhydride) 
nanoparticles; PTX-NP2: paclitaxel loaded in nanoparticles pegylated with PEG 
2000; PTX-NP6: paclitaxel loaded in nanoparticles pegylated with PEG 6000; 
PTX-NP10: paclitaxel loaded in nanoparticles pegylated with PEG 10000. 
 
 
Experimental 
conditions 
Papp 
(10-6 cm/s) 
Absorption 
enhancement 
ratio (R) 
Taxol M-S; 37ºC 1.2 ± 0.2 1 
PTX-NP M-S; 37ºC 2.1 ± 0.2 1.8 
PTX-NP2 M-S; 37ºC 8.5 ± 0.5*** 7.2 
PTX-NP2 M-S; 4ºC 10 ± 3*** 8.5 
PTX-NP2 M-S; Pg – P inhibition (verapamil), 37ºC 25 ± 5*** 21 
PTX-NP2 M-S; No bioadhesion, 37ºC 0.3 ± 0.5 0.3 
PTX-NP6 M-S; 37ºC 8.7 ± 1.5*** 7.3 
PTX-NP10 M-S; 37ºC 4.0 ± 1.2*** 3.3 
Taxol S-M: 37ºC 32 ± 2 27 
PTX-NP2 S-M; 37ºC 22 ± 2 18 
*** p<0.005 all groups vs. commercial Taxol® (U Mann-Whitney test).  
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Table 3. Pharmacokinetic parameters of the different formulations tested. PTX-
NP: paclitaxel-loaded poly(anhydride) nanoparticles; PTX-NP2: paclitaxel 
loaded in nanoparticles pegylated with PEG 2000; PTX-NP6: paclitaxel loaded 
in nanoparticles pegylated with PEG 6000; PTX-NP10: paclitaxel loaded in 
nanoparticles pegylated with PEG 10000. 
 
Formulation Route AUC (µg h/ml) 
Cmax 
(µg) 
Tmax 
(h) 
MRT 
(h) 
T1/2 z 
(h-1) Fr 
Taxol® i.v. 81±4 204±2 0.01 1.7±0.2 2.6±0.4 100 
Taxol® Oral ND 15 ND ND ND 0 
PTX-NP2 Oral 56±3*‡ 2.1±0.1 5.8 26±1 9.3±0.5 70 
PTX-NP6 Oral 32±2**† 1.9±0.1 3.0 27±1 6.2±0.3 40 
PTX-NP10 Oral 13±1** 1.4±0.1 3.3 18±1 29±2 16 
PTX-NP Oral 7.4±0.9** 0.2±0.0 3.8 31±1 27±1 9.1 
* Man-Whitney U-test between PTX-NP2 vs Taxol® i.v. (p-value < 0.05).  
** Man-Whitney U-test between PTX-NP6, PTX-NP10 and PTX-NP vs Taxol® 
i.v. (p-value < 0.01). 
† Man-Whitney U-test between PTX-NP6 vs PTX-NP10 and PTX-NP (p-value < 
0.05).  
‡ Man-Whitney U-test between PTX-NP2 vs PTX-NP6, PTX-NP10 and PTX-NP 
(p-value < 0.01).  
AUC0-∞: area under the concentration-time curve from time 0 to ∞; Cmax: peak of 
maximum concentration; Tmax: time to peak concentration; MRT: mean 
residence time; t1/2z: half-life of the terminal phase. 
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Figure 1. Influence of the PTX/poly(anhydride) ratio on the drug loading of the 
resulting nanoparticles. Data expressed as the mean±S.D. (n = 3). Experimental 
conditions: PVM/MA: 100 mg. PEG/poly(anhydride) ratio of 0.125. Incubation 
time: 1 hour. PTX-NP: paclitaxel-loaded poly(anhydride) nanoparticles; PTX-
NP2: paclitaxel loaded in nanoparticles pegylated with PEG 2000; PTX-NP6: 
paclitaxel loaded in nanoparticles pegylated with PEG 6000; PTX-NP10: 
paclitaxel loaded in nanoparticles pegylated with PEG 10000. 
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Figure 2. Adhered fractions of nanoparticles in the different parts of rat 
gastrointestinal tract 1 h (A) and 3 h (B) post-administration. The adhered 
fractions are presented as a percentage of the initial administered dose (mean ± 
SD; n=6). 
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Figure 3. Plasma paclitaxel concentration-time profile after the intravenous 
administration of a 10 mg/kg dose of Taxol. Data are expressed as mean ± 
SD, n=6 per time point. 

Figure 4.  Paclitaxel plasma levels after the oral administration of a single dose 
of 10 mg/kg. PTX-NP: paclitaxel-loaded poly(anhydride) nanoparticles; PTX-
NP2: paclitaxel loaded in nanoparticles pegylated with PEG 2000; PTX-NP6: 
paclitaxel loaded in nanoparticles pegylated with PEG 6000; PTX-NP10: 
paclitaxel loaded in nanoparticles pegylated with PEG 10000. Data expressed 
as mean ± SD (n=6). 
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